Cargando…

1329. Burden of Respiratory Syncytial Virus (RSV) Infection among Hospitalized Older Adults and Those with Underlying Chronic Obstructive Pulmonary Disease (COPD) or Congestive Heart Failure (CHF)

BACKGROUND: The burden of Respiratory Syncytial Virus (RSV)-associated hospitalization in adults is incompletely understood. The COVID-19 pandemic has resulted in multiple public health measures (e.g., social distancing, handwashing, masking) to decrease SARS-CoV-2 transmission, which could impact R...

Descripción completa

Detalles Bibliográficos
Autores principales: Salazar, Luis W, Tippett, Ashley, Hussaini, Laila, Taylor, Megan, Reese, Olivia, Ciric, Caroline, Bristow, Laurel, Patel, Vikash, Li, Wensheng, Hsiao, Hui-mien, Stephens, Kathy, Gibson, Theda, Cheng, Andrew, Kay, Ariel, Swerdlow, David L, Hubler, Robin, Lopman, Ben, Anderson, Larry, Rostad, Christina A, Rouphael, Nadine, Anderson, Evan J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644080/
http://dx.doi.org/10.1093/ofid/ofab466.1521
_version_ 1784610003301171200
author Salazar, Luis W
Tippett, Ashley
Hussaini, Laila
Taylor, Megan
Reese, Olivia
Ciric, Caroline
Bristow, Laurel
Patel, Vikash
Li, Wensheng
Hsiao, Hui-mien
Stephens, Kathy
Gibson, Theda
Cheng, Andrew
Kay, Ariel
Swerdlow, David L
Hubler, Robin
Lopman, Ben
Anderson, Larry
Rostad, Christina A
Rouphael, Nadine
Rouphael, Nadine
Anderson, Evan J
author_facet Salazar, Luis W
Tippett, Ashley
Hussaini, Laila
Taylor, Megan
Reese, Olivia
Ciric, Caroline
Bristow, Laurel
Patel, Vikash
Li, Wensheng
Hsiao, Hui-mien
Stephens, Kathy
Gibson, Theda
Cheng, Andrew
Kay, Ariel
Swerdlow, David L
Hubler, Robin
Lopman, Ben
Anderson, Larry
Rostad, Christina A
Rouphael, Nadine
Rouphael, Nadine
Anderson, Evan J
author_sort Salazar, Luis W
collection PubMed
description BACKGROUND: The burden of Respiratory Syncytial Virus (RSV)-associated hospitalization in adults is incompletely understood. The COVID-19 pandemic has resulted in multiple public health measures (e.g., social distancing, handwashing, masking) to decrease SARS-CoV-2 transmission, which could impact RSV-associated hospitalizations. We sought to compare RSV-associated hospitalizations from 2 pre- and one mid-COVID-19 winter viral respiratory seasons. METHODS: We conducted an IRB-approved prospective surveillance at two Atlanta-area hospitals during the winter respiratory viral seasons from Oct 2018–Apr 2021 for adults ≥ 50 years of age admitted with acute respiratory infections (ARI) and adults of any age with COPD or CHF-related admissions. Adults were eligible if they were residents of an 8 county region surrounding Atlanta, Georgia. Those with symptoms > 14 days were excluded. Standard of care test results were included. Asymptomatic adults ≥ 50 years of age were enrolled as controls in Seasons 1 and 2. Nasopharyngeal swabs from cases and controls were tested for RSV using BioFire® FilmArray® Respiratory Viral Panel (RVP). We compared the demographic features and outcomes of RSV+ cases and controls. RESULTS: RSV was detected in 71/2,728 (2.6%) hospitalized adults with ARI, CHF, or COPD and 4/466 (0.9%) controls. In Season 1, RSV occurred in 5.9% (35/596 patients), in Season 2 3.6% (35/970 patients), but in only 0.09% (1/1,162 patients) in Season 3 (P < 0.001 for both seasons). RSV detection in Season 3 was similar to RSV detection among controls during Seasons 1 and 2 (P=0.6). Median age of cases and controls was 67 years (Table 1). Of cases with RSV 11% were admitted to the ICU and two required mechanical ventilation. The majority of hospitalized patients were discharged home (95.8%) with a median length of hospitalization of three days (IQR 2-7). Table 1. Demographic Features and Outcomes Among RSV-Positive Hospitalized Adults. [Image: see text] CONCLUSION: Over 3 seasons, RSV was detected in 2.6% of adults admitted to the hospital with ARI, CHF or COPD. The rate of RSV dramatically declined during the 2020-21 winter respiratory viral season, likely due to public health measures implemented in response to COVID-19. DISCLOSURES: David L. Swerdlow, MD, Pfizer Vaccines (Employee) Robin Hubler, MS, Pfizer Inc. (Employee) Larry Anderson, MD, ADVI (Consultant)Bavarian Nordic (Consultant)Novavax (Consultant)Phizer (Grant/Research Support, Scientific Research Study Investigator)Sciogen (Research Grant or Support) Christina A. Rostad, MD, BioFire Inc, GSK, MedImmune, Micron, Janssen, Merck, Moderna, Novavax, PaxVax, Pfizer, Regeneron, Sanofi-Pasteur. (Grant/Research Support, Scientific Research Study Investigator, Research Grant or Support)Meissa Vaccines (Other Financial or Material Support, Co-inventor of patented RSV vaccine technology unrelated to this manuscript, which has been licensed to Meissa Vaccines, Inc.) Nadine Rouphael, MD, pfizer, sanofi, lily, quidel, merck (Grant/Research Support) Nadine Rouphael, MD, Lilly (Individual(s) Involved: Self): Emory Study PI, Grant/Research Support; Merck (Individual(s) Involved: Self): Emory study PI, Grant/Research Support; Pfizer: I conduct as co-PI the RSV PFIZER study at Emory, Research Grant; Pfizer (Individual(s) Involved: Self): Grant/Research Support, I conduct as co-PI the RSV PFIZER study at Emory; Quidel (Individual(s) Involved: Self): Emory Study PI, Grant/Research Support; Sanofi Pasteur (Individual(s) Involved: Self): Chair phase 3 COVID vaccine, Grant/Research Support Evan J. Anderson, MD, GSK (Scientific Research Study Investigator)Janssen (Consultant, Scientific Research Study Investigator, Advisor or Review Panel member)Kentucky Bioprocessing, Inc (Advisor or Review Panel member)MedImmune (Scientific Research Study Investigator)Medscape (Consultant)Merck (Scientific Research Study Investigator)Micron (Scientific Research Study Investigator)PaxVax (Scientific Research Study Investigator)Pfizer (Consultant, Grant/Research Support, Scientific Research Study Investigator)Regeneron (Scientific Research Study Investigator)Sanofi Pasteur (Consultant, Scientific Research Study Investigator)
format Online
Article
Text
id pubmed-8644080
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-86440802021-12-06 1329. Burden of Respiratory Syncytial Virus (RSV) Infection among Hospitalized Older Adults and Those with Underlying Chronic Obstructive Pulmonary Disease (COPD) or Congestive Heart Failure (CHF) Salazar, Luis W Tippett, Ashley Hussaini, Laila Taylor, Megan Reese, Olivia Ciric, Caroline Bristow, Laurel Patel, Vikash Li, Wensheng Hsiao, Hui-mien Stephens, Kathy Gibson, Theda Cheng, Andrew Kay, Ariel Swerdlow, David L Hubler, Robin Lopman, Ben Anderson, Larry Rostad, Christina A Rouphael, Nadine Rouphael, Nadine Anderson, Evan J Open Forum Infect Dis Poster Abstracts BACKGROUND: The burden of Respiratory Syncytial Virus (RSV)-associated hospitalization in adults is incompletely understood. The COVID-19 pandemic has resulted in multiple public health measures (e.g., social distancing, handwashing, masking) to decrease SARS-CoV-2 transmission, which could impact RSV-associated hospitalizations. We sought to compare RSV-associated hospitalizations from 2 pre- and one mid-COVID-19 winter viral respiratory seasons. METHODS: We conducted an IRB-approved prospective surveillance at two Atlanta-area hospitals during the winter respiratory viral seasons from Oct 2018–Apr 2021 for adults ≥ 50 years of age admitted with acute respiratory infections (ARI) and adults of any age with COPD or CHF-related admissions. Adults were eligible if they were residents of an 8 county region surrounding Atlanta, Georgia. Those with symptoms > 14 days were excluded. Standard of care test results were included. Asymptomatic adults ≥ 50 years of age were enrolled as controls in Seasons 1 and 2. Nasopharyngeal swabs from cases and controls were tested for RSV using BioFire® FilmArray® Respiratory Viral Panel (RVP). We compared the demographic features and outcomes of RSV+ cases and controls. RESULTS: RSV was detected in 71/2,728 (2.6%) hospitalized adults with ARI, CHF, or COPD and 4/466 (0.9%) controls. In Season 1, RSV occurred in 5.9% (35/596 patients), in Season 2 3.6% (35/970 patients), but in only 0.09% (1/1,162 patients) in Season 3 (P < 0.001 for both seasons). RSV detection in Season 3 was similar to RSV detection among controls during Seasons 1 and 2 (P=0.6). Median age of cases and controls was 67 years (Table 1). Of cases with RSV 11% were admitted to the ICU and two required mechanical ventilation. The majority of hospitalized patients were discharged home (95.8%) with a median length of hospitalization of three days (IQR 2-7). Table 1. Demographic Features and Outcomes Among RSV-Positive Hospitalized Adults. [Image: see text] CONCLUSION: Over 3 seasons, RSV was detected in 2.6% of adults admitted to the hospital with ARI, CHF or COPD. The rate of RSV dramatically declined during the 2020-21 winter respiratory viral season, likely due to public health measures implemented in response to COVID-19. DISCLOSURES: David L. Swerdlow, MD, Pfizer Vaccines (Employee) Robin Hubler, MS, Pfizer Inc. (Employee) Larry Anderson, MD, ADVI (Consultant)Bavarian Nordic (Consultant)Novavax (Consultant)Phizer (Grant/Research Support, Scientific Research Study Investigator)Sciogen (Research Grant or Support) Christina A. Rostad, MD, BioFire Inc, GSK, MedImmune, Micron, Janssen, Merck, Moderna, Novavax, PaxVax, Pfizer, Regeneron, Sanofi-Pasteur. (Grant/Research Support, Scientific Research Study Investigator, Research Grant or Support)Meissa Vaccines (Other Financial or Material Support, Co-inventor of patented RSV vaccine technology unrelated to this manuscript, which has been licensed to Meissa Vaccines, Inc.) Nadine Rouphael, MD, pfizer, sanofi, lily, quidel, merck (Grant/Research Support) Nadine Rouphael, MD, Lilly (Individual(s) Involved: Self): Emory Study PI, Grant/Research Support; Merck (Individual(s) Involved: Self): Emory study PI, Grant/Research Support; Pfizer: I conduct as co-PI the RSV PFIZER study at Emory, Research Grant; Pfizer (Individual(s) Involved: Self): Grant/Research Support, I conduct as co-PI the RSV PFIZER study at Emory; Quidel (Individual(s) Involved: Self): Emory Study PI, Grant/Research Support; Sanofi Pasteur (Individual(s) Involved: Self): Chair phase 3 COVID vaccine, Grant/Research Support Evan J. Anderson, MD, GSK (Scientific Research Study Investigator)Janssen (Consultant, Scientific Research Study Investigator, Advisor or Review Panel member)Kentucky Bioprocessing, Inc (Advisor or Review Panel member)MedImmune (Scientific Research Study Investigator)Medscape (Consultant)Merck (Scientific Research Study Investigator)Micron (Scientific Research Study Investigator)PaxVax (Scientific Research Study Investigator)Pfizer (Consultant, Grant/Research Support, Scientific Research Study Investigator)Regeneron (Scientific Research Study Investigator)Sanofi Pasteur (Consultant, Scientific Research Study Investigator) Oxford University Press 2021-12-04 /pmc/articles/PMC8644080/ http://dx.doi.org/10.1093/ofid/ofab466.1521 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Poster Abstracts
Salazar, Luis W
Tippett, Ashley
Hussaini, Laila
Taylor, Megan
Reese, Olivia
Ciric, Caroline
Bristow, Laurel
Patel, Vikash
Li, Wensheng
Hsiao, Hui-mien
Stephens, Kathy
Gibson, Theda
Cheng, Andrew
Kay, Ariel
Swerdlow, David L
Hubler, Robin
Lopman, Ben
Anderson, Larry
Rostad, Christina A
Rouphael, Nadine
Rouphael, Nadine
Anderson, Evan J
1329. Burden of Respiratory Syncytial Virus (RSV) Infection among Hospitalized Older Adults and Those with Underlying Chronic Obstructive Pulmonary Disease (COPD) or Congestive Heart Failure (CHF)
title 1329. Burden of Respiratory Syncytial Virus (RSV) Infection among Hospitalized Older Adults and Those with Underlying Chronic Obstructive Pulmonary Disease (COPD) or Congestive Heart Failure (CHF)
title_full 1329. Burden of Respiratory Syncytial Virus (RSV) Infection among Hospitalized Older Adults and Those with Underlying Chronic Obstructive Pulmonary Disease (COPD) or Congestive Heart Failure (CHF)
title_fullStr 1329. Burden of Respiratory Syncytial Virus (RSV) Infection among Hospitalized Older Adults and Those with Underlying Chronic Obstructive Pulmonary Disease (COPD) or Congestive Heart Failure (CHF)
title_full_unstemmed 1329. Burden of Respiratory Syncytial Virus (RSV) Infection among Hospitalized Older Adults and Those with Underlying Chronic Obstructive Pulmonary Disease (COPD) or Congestive Heart Failure (CHF)
title_short 1329. Burden of Respiratory Syncytial Virus (RSV) Infection among Hospitalized Older Adults and Those with Underlying Chronic Obstructive Pulmonary Disease (COPD) or Congestive Heart Failure (CHF)
title_sort 1329. burden of respiratory syncytial virus (rsv) infection among hospitalized older adults and those with underlying chronic obstructive pulmonary disease (copd) or congestive heart failure (chf)
topic Poster Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644080/
http://dx.doi.org/10.1093/ofid/ofab466.1521
work_keys_str_mv AT salazarluisw 1329burdenofrespiratorysyncytialvirusrsvinfectionamonghospitalizedolderadultsandthosewithunderlyingchronicobstructivepulmonarydiseasecopdorcongestiveheartfailurechf
AT tippettashley 1329burdenofrespiratorysyncytialvirusrsvinfectionamonghospitalizedolderadultsandthosewithunderlyingchronicobstructivepulmonarydiseasecopdorcongestiveheartfailurechf
AT hussainilaila 1329burdenofrespiratorysyncytialvirusrsvinfectionamonghospitalizedolderadultsandthosewithunderlyingchronicobstructivepulmonarydiseasecopdorcongestiveheartfailurechf
AT taylormegan 1329burdenofrespiratorysyncytialvirusrsvinfectionamonghospitalizedolderadultsandthosewithunderlyingchronicobstructivepulmonarydiseasecopdorcongestiveheartfailurechf
AT reeseolivia 1329burdenofrespiratorysyncytialvirusrsvinfectionamonghospitalizedolderadultsandthosewithunderlyingchronicobstructivepulmonarydiseasecopdorcongestiveheartfailurechf
AT ciriccaroline 1329burdenofrespiratorysyncytialvirusrsvinfectionamonghospitalizedolderadultsandthosewithunderlyingchronicobstructivepulmonarydiseasecopdorcongestiveheartfailurechf
AT bristowlaurel 1329burdenofrespiratorysyncytialvirusrsvinfectionamonghospitalizedolderadultsandthosewithunderlyingchronicobstructivepulmonarydiseasecopdorcongestiveheartfailurechf
AT patelvikash 1329burdenofrespiratorysyncytialvirusrsvinfectionamonghospitalizedolderadultsandthosewithunderlyingchronicobstructivepulmonarydiseasecopdorcongestiveheartfailurechf
AT liwensheng 1329burdenofrespiratorysyncytialvirusrsvinfectionamonghospitalizedolderadultsandthosewithunderlyingchronicobstructivepulmonarydiseasecopdorcongestiveheartfailurechf
AT hsiaohuimien 1329burdenofrespiratorysyncytialvirusrsvinfectionamonghospitalizedolderadultsandthosewithunderlyingchronicobstructivepulmonarydiseasecopdorcongestiveheartfailurechf
AT stephenskathy 1329burdenofrespiratorysyncytialvirusrsvinfectionamonghospitalizedolderadultsandthosewithunderlyingchronicobstructivepulmonarydiseasecopdorcongestiveheartfailurechf
AT gibsontheda 1329burdenofrespiratorysyncytialvirusrsvinfectionamonghospitalizedolderadultsandthosewithunderlyingchronicobstructivepulmonarydiseasecopdorcongestiveheartfailurechf
AT chengandrew 1329burdenofrespiratorysyncytialvirusrsvinfectionamonghospitalizedolderadultsandthosewithunderlyingchronicobstructivepulmonarydiseasecopdorcongestiveheartfailurechf
AT kayariel 1329burdenofrespiratorysyncytialvirusrsvinfectionamonghospitalizedolderadultsandthosewithunderlyingchronicobstructivepulmonarydiseasecopdorcongestiveheartfailurechf
AT swerdlowdavidl 1329burdenofrespiratorysyncytialvirusrsvinfectionamonghospitalizedolderadultsandthosewithunderlyingchronicobstructivepulmonarydiseasecopdorcongestiveheartfailurechf
AT hublerrobin 1329burdenofrespiratorysyncytialvirusrsvinfectionamonghospitalizedolderadultsandthosewithunderlyingchronicobstructivepulmonarydiseasecopdorcongestiveheartfailurechf
AT lopmanben 1329burdenofrespiratorysyncytialvirusrsvinfectionamonghospitalizedolderadultsandthosewithunderlyingchronicobstructivepulmonarydiseasecopdorcongestiveheartfailurechf
AT andersonlarry 1329burdenofrespiratorysyncytialvirusrsvinfectionamonghospitalizedolderadultsandthosewithunderlyingchronicobstructivepulmonarydiseasecopdorcongestiveheartfailurechf
AT rostadchristinaa 1329burdenofrespiratorysyncytialvirusrsvinfectionamonghospitalizedolderadultsandthosewithunderlyingchronicobstructivepulmonarydiseasecopdorcongestiveheartfailurechf
AT rouphaelnadine 1329burdenofrespiratorysyncytialvirusrsvinfectionamonghospitalizedolderadultsandthosewithunderlyingchronicobstructivepulmonarydiseasecopdorcongestiveheartfailurechf
AT rouphaelnadine 1329burdenofrespiratorysyncytialvirusrsvinfectionamonghospitalizedolderadultsandthosewithunderlyingchronicobstructivepulmonarydiseasecopdorcongestiveheartfailurechf
AT andersonevanj 1329burdenofrespiratorysyncytialvirusrsvinfectionamonghospitalizedolderadultsandthosewithunderlyingchronicobstructivepulmonarydiseasecopdorcongestiveheartfailurechf